Metformin for Parkinson's Disease - Phase 2/3 Trial (NCT07229651)

Metformin Parkinsons NCT07229651

Overview

Metformin, a widely used Type 2 diabetes medication, is being investigated as a potential disease-modifying treatment for Parkinson's disease. This clinical trial (NCT07229651) evaluates whether metformin can slow Parkinson's disease progression through AMPK activation and downstream neuroprotective mechanisms. The trial represents a significant step in drug repurposing for neurodegenerative diseases, leveraging metformin's well-established safety profile and known CNS penetration.

Metformin's potential in PD stems from its ability to activate AMPK, a central cellular energy sensor that coordinates metabolic homeostasis and activates downstream pathways critical for neuronal survival. By targeting fundamental cellular processes involved in neurodegeneration, metformin may offer disease-modifying benefits rather than merely symptomatic relief.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07229651 |
| Phase | Phase 2/3 |
| Status | Recruiting |
| Sponsor | Multiple academic centers |
| Intervention | Metformin hydrochloride |
| Dose | 500-1000 mg daily (titrated) |
| Duration | 52 weeks treatment |
| Sample Size | Approximately 200 participants |
| Primary Endpoint | Change in MDS-UPDRS Part 3 score |
| Key Secondary | Change in DAT-SPECT imaging |

Background and Rationale

Metformin Mechanism

Metformin Parkinsons NCT07229651

Overview

Metformin, a widely used Type 2 diabetes medication, is being investigated as a potential disease-modifying treatment for Parkinson's disease. This clinical trial (NCT07229651) evaluates whether metformin can slow Parkinson's disease progression through AMPK activation and downstream neuroprotective mechanisms. The trial represents a significant step in drug repurposing for neurodegenerative diseases, leveraging metformin's well-established safety profile and known CNS penetration.

Metformin's potential in PD stems from its ability to activate AMPK, a central cellular energy sensor that coordinates metabolic homeostasis and activates downstream pathways critical for neuronal survival. By targeting fundamental cellular processes involved in neurodegeneration, metformin may offer disease-modifying benefits rather than merely symptomatic relief.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07229651 |
| Phase | Phase 2/3 |
| Status | Recruiting |
| Sponsor | Multiple academic centers |
| Intervention | Metformin hydrochloride |
| Dose | 500-1000 mg daily (titrated) |
| Duration | 52 weeks treatment |
| Sample Size | Approximately 200 participants |
| Primary Endpoint | Change in MDS-UPDRS Part 3 score |
| Key Secondary | Change in DAT-SPECT imaging |

Background and Rationale

Metformin Mechanism

Metformin activates AMP-activated protein kinase (AMPK), a central cellular energy sensor that coordinates metabolic homeostasis[@kuan2019][@aggleton2020]. AMPK serves as a master regulator of cellular energy metabolism, activating catabolic processes while inhibiting anabolic ones when energy levels are low. This activation triggers a cascade of protective cellular responses particularly relevant to neurodegeneration.

The molecular mechanism of metformin involves several key steps:

Preclinical Evidence

Strong preclinical evidence supports metformin in PD[@wu2018][@perez2022]:

MPTP Models

• Metformin protects dopaminergic neurons in MPTP-treated mice
• Reduces loss of tyrosine hydroxylase-positive neurons in the substantia nigra
• Improves motor performance in MPTP-challenged animals

• Reduces aggregation through autophagy enhancement
• Decreases phosphorylated α-synuclein burden
• Improves behavioral deficits in α-synuclein transgenic models

• Reduces microglial activation and pro-inflammatory cytokine production
• Attenuates neuroinflammation-induced dopaminergic neuron loss
• Modulates peripheral immune responses

• Improves mitochondrial function and ATP production
• Enhances mitochondrial biogenesis through PGC-1α activation[@song2018]
• Reduces oxidative stress markers

Rationale for Repurposing

Metformin offers several advantages as a repurposed drug:

• Safety profile: Well-established safety in millions of patients over decades
• BBB penetration: Demonstrated CNS penetration in human studies
• Cost: Generic availability makes it accessible
• Accessibility: Oral administration simplifies delivery
• Dosing: Well-characterized dose-response relationship
• Pharmacokinetics: Well-understood absorption, distribution, metabolism, and excretion

Trial Design

Study Population

Inclusion Criteria

• Age 40-80 years
• Parkinson's disease diagnosis (UK Brain Bank criteria)
• Hoehn & Yahr stage 1-3
• Disease duration 1-10 years
• Stable PD medication for ≥4 weeks
• Montreal Cognitive Assessment (MoCA) score ≥24

• Diabetes mellitus (excluded to isolate PD effect)
• Significant cognitive impairment (MMSE <24)
• Previous metformin use (within 12 months)
• Renal impairment (eGFR <60 mL/min/1.73m²)
• Hepatic impairment
• Cardiovascular events within 6 months
• Current participation in other clinical trials

Randomization and Blinding

This trial employs a randomized, double-blind, placebo-controlled design:

• Participants randomized 1:1 to metformin or placebo
• Matching tablets ensure blinding
• Independent statistician oversees randomization
• Interim analysis planned at 50% enrollment

Endpoints

Primary

• Change in MDS-UPDRS Part 3 (motor) score at 52 weeks
• Change in DAT-SPECT imaging (secondary primary)

• Motor complications development (dyskinesias, motor fluctuations)
• Non-motor symptoms (cognitive, autonomic, sleep)
• Quality of life (PDQ-39)
• CSF biomarkers (α-synuclein, tau, NfL)
• Hospitalization rates
• Adverse event frequency and severity

Assessment Schedule

| Visit | Timing | Assessments |
|-------|--------|-------------|
| Screening | Week -4 to 0 | Medical history, physical, cognitive assessment |
| Baseline | Week 0 | MDS-UPDRS, DAT-SPECT, CSF collection, randomization |
| Week 13 | Week 13 | MDS-UPDRS, safety labs, adverse events |
| Week 26 | Week 26 | MDS-UPDRS, PDQ-39, secondary endpoints |
| Week 39 | Week 39 | MDS-UPDRS, safety assessment |
| Week 52 | Week 52 | All primary and secondary endpoints, DAT-SPECT |

Clinical Translation

Biomarker Connections

Metformin treatment may be monitored through multiple biomarker categories[@perez2022]:

Metabolic Biomarkers

• Fasting glucose and insulin levels
• HbA1c (glycated hemoglobin)
• Body mass index and weight changes
• Lipid panel (cholesterol, triglycerides)

• Plasma and CSF Neurofilament light chain (NfL)
• CSF α-synuclein RT-QuIC
• Total tau and phosphorylated tau
• Amyloid-β 1-42

• DAT-SPECT for dopaminergic integrity
• MRI for brain volume changes
• PET imaging for amyloid/tau (subset)

Mechanistic Pathways

Patient Impact

Potential Benefits

• Disease modification through AMPK activation
• Improved glucose metabolism in brain
• Reduced neuroinflammation
• Enhanced autophagy of misfolded proteins
• Potential for combined motor and non-motor symptom benefits
• May reduce need for escalating dopaminergic medications

• May require high doses for optimal CNS effect
• Gastrointestinal side effects possible (nausea, diarrhea)
• Long-term safety in non-diabetic PD population not fully characterized
• Potential for vitamin B12 deficiency with long-term use
• Drug interactions with common PD medications

Competitive Landscape

Metformin enters a competitive field of repurposed drugs for PD:

| Agent | Mechanism | Stage | Notes |
|-------|-----------|-------|-------|
| Metformin | AMPK activator | Phase 2/3 | Repurposed generic, oral |
| Exenatide | GLP-1 agonist | Phase 3 | Subcutaneous injection |
| GLP-1 analogs (linclatide) | GLP-1 agonist | Phase 2/3 | Multiple candidates |
| Ambroxol | Glucocerebrosidase chaperone | Phase 2 | Targets GBA mutations |
| Inosine | Urate elevation | Phase 3 | Antioxidant approach |
| Azilect | MAO-B inhibition | Approved | Disease-modifying claims |

Research Context

Supporting Evidence

The trial builds on extensive preclinical data and some human correlative studies:

Clinical Observations in Diabetes

• Reduced PD incidence in metformin-treated diabetic patients (epidemiological studies)
• Improved cognitive outcomes in diabetic patients on metformin
• Established CNS penetration in humans

• AMPK activation in post-mortem PD brain tissue
• Autophagy impairment in PD models and patient tissue
• Mitochondrial dysfunction as central to PD pathogenesis

Ongoing Trials

Several trials are investigating metabolic interventions in PD:

• GLP-1 receptor agonists (exenatide, liraglutide)
• Inosine for urate elevation
• Dietary interventions (fasting, calorie restriction)
• Ketogenic diet trials
• Mitochondrial-targeted antioxidants

Future Directions

If successful, metformin could become a cornerstone of disease-modifying therapy in PD:

• Combination approaches with other neuroprotective agents
• Biomarker-driven patient selection
• Prevention trials in at-risk populations
• Pediatric formulations for earlier intervention

References